Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived mesenchymal stromal cells + everolimus
- Development stage
- Unknown
- Lead developer
- Leiden University Medical Center
- Modality
- Stem Cell Therapies → Cell Therapies, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Autologous bone marrow-derived mesenchymal stromal cells (MSCs) in combination with everolimus is an experimental therapeutic regimen developed by Leiden University Medical Center (LUMC) for renal transplant recipients. The therapy involves the intravenous administration of ex vivo expanded autologous MSCs, which possess potent immunomodulatory, anti-inflammatory, and pro-regenerative properties. These cells are used in conjunction with everolimus, a small molecule inhibitor of the mechanistic target of rapamycin (mTOR), to provide maintenance immunosuppression. The primary clinical objective of this combination is to facilitate the withdrawal of tacrolimus, thereby reducing calcineurin inhibitor-induced nephrotoxicity and renal fibrosis while maintaining graft stability and reducing the risk of opportunistic infections.
- Brand names
- Certican
- Other names
- MSCs + everolimusautologous MSCs + everolimusLUMC-MSCs + everolimus
02
Targets
Mechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on autologous bone marrow-derived mesenchymal stromal cells + everolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived mesenchymal stromal cells + everolimus.